دورية أكاديمية
أعرض في EDS

Emerging role of natural products in cancer immunotherapy.

التفاصيل البيبلوغرافية
العنوان: Emerging role of natural products in cancer immunotherapy.
المؤلفون: Dong S; Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China., Guo X; Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China., Han F; School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China., He Z; Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China., Wang Y; Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
المصدر: Acta pharmaceutica Sinica. B [Acta Pharm Sin B] 2022 Mar; Vol. 12 (3), pp. 1163-1185. Date of Electronic Publication: 2021 Aug 21.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101600560 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2211-3835 (Print) Linking ISSN: 22113835 NLM ISO Abbreviation: Acta Pharm Sin B Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier, 2011-
مستخلص: Cancer immunotherapy has become a new generation of anti-tumor treatment, but its indications still focus on several types of tumors that are sensitive to the immune system. Therefore, effective strategies that can expand its indications and enhance its efficiency become the key element for the further development of cancer immunotherapy. Natural products are reported to have this effect on cancer immunotherapy, including cancer vaccines, immune-check points inhibitors, and adoptive immune-cells therapy. And the mechanism of that is mainly attributed to the remodeling of the tumor-immunosuppressive microenvironment, which is the key factor that assists tumor to avoid the recognition and attack from immune system and cancer immunotherapy. Therefore, this review summarizes and concludes the natural products that reportedly improve cancer immunotherapy and investigates the mechanism. And we found that saponins, polysaccharides, and flavonoids are mainly three categories of natural products, which reflected significant effects combined with cancer immunotherapy through reversing the tumor-immunosuppressive microenvironment. Besides, this review also collected the studies about nano-technology used to improve the disadvantages of natural products. All of these studies showed the great potential of natural products in cancer immunotherapy.
(© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.)
References: Cell. 2017 Feb 9;168(4):707-723. (PMID: 28187290)
Cancer Res. 2009 Dec 1;69(23):8958-66. (PMID: 19903839)
Clin Cancer Res. 2003 Nov 1;9(14):5214-20. (PMID: 14614001)
Nat Commun. 2020 Jul 3;11(1):3325. (PMID: 32620755)
Cancer Lett. 2019 Sep 10;459:72-85. (PMID: 31176742)
Nat Rev Clin Oncol. 2014 Sep;11(9):509-24. (PMID: 25001465)
Oncotarget. 2017 Oct 4;8(55):93712-93728. (PMID: 29212184)
Onco Targets Ther. 2019 Dec 12;12:10917-10930. (PMID: 31849495)
Nat Rev Immunol. 2018 Mar;18(3):168-182. (PMID: 29226910)
Int J Rheum Dis. 2019 Feb;22(2):200-206. (PMID: 30338648)
Nature. 2014 Nov 27;515(7528):577-81. (PMID: 25428507)
Science. 2018 Mar 23;359(6382):1355-1360. (PMID: 29567706)
Oncotarget. 2015 Oct 6;6(30):29543-54. (PMID: 26338963)
Cancer Immunol Immunother. 2019 Jul;68(7):1073-1085. (PMID: 31161238)
Food Funct. 2020 Jan 29;11(1):456-471. (PMID: 31830168)
Nat Rev Immunol. 2003 Feb;3(2):133-46. (PMID: 12563297)
Sci Rep. 2019 Aug 9;9(1):11560. (PMID: 31399602)
Cancer Lett. 2016 Oct 1;380(2):424-433. (PMID: 27378243)
Semin Cancer Biol. 2006 Apr;16(2):124-36. (PMID: 16443370)
Oncol Lett. 2013 Jul;6(1):256-260. (PMID: 23946814)
Curr Opin Immunol. 2010 Feb;22(1):109-17. (PMID: 20171863)
Biomaterials. 2020 Mar;235:119769. (PMID: 31986348)
Nature. 1998 Mar 19;392(6673):245-52. (PMID: 9521319)
Clin Exp Immunol. 2009 Feb;155(2):140-6. (PMID: 19077084)
DNA Cell Biol. 2017 Dec;36(12):1168-1177. (PMID: 29058460)
Nat Rev Immunol. 2018 Mar;18(3):183-194. (PMID: 29279613)
Pharmacol Res. 2019 Oct;148:104417. (PMID: 31473343)
Oncoimmunology. 2014 Dec 13;3(9):e955691. (PMID: 25941621)
Int J Cancer. 2000 Mar 1;85(5):659-66. (PMID: 10699946)
Oncol Rep. 2013 Jan;29(1):117-24. (PMID: 23076367)
Eur J Pharmacol. 2010 Sep 25;643(2-3):297-303. (PMID: 20599915)
Int Immunopharmacol. 2006 Nov;6(11):1729-35. (PMID: 16979128)
Signal Transduct Target Ther. 2021 Feb 20;6(1):72. (PMID: 33608497)
Cell Mol Immunol. 2006 Aug;3(4):291-5. (PMID: 16978538)
J Exp Med. 1999 Aug 2;190(3):355-66. (PMID: 10430624)
Biomed Pharmacother. 2020 Jan;121:109570. (PMID: 31710893)
EBioMedicine. 2019 Feb;40:151-162. (PMID: 30711516)
Clin Cancer Res. 2000 May;6(5):1693-701. (PMID: 10815887)
Integr Cancer Ther. 2017 Sep;16(3):319-328. (PMID: 27252074)
J Neuroimmunol. 2020 Jun 15;343:577217. (PMID: 32244040)
Cancer Prev Res (Phila). 2012 Mar;5(3):444-52. (PMID: 22135043)
J Hematol Oncol. 2009 Jun 10;2:25. (PMID: 19515245)
Clin Cancer Res. 2019 Mar 15;25(6):1702-1708. (PMID: 30413526)
Cancer Lett. 2001 Apr 26;165(2):139-45. (PMID: 11275362)
Molecules. 2020 Jan 08;25(2):. (PMID: 31936263)
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188338. (PMID: 31904399)
Vaccine. 2010 Feb 3;28(5):1241-52. (PMID: 19969119)
Nat Commun. 2020 Jan 30;11(1):622. (PMID: 32001695)
J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. (PMID: 30373602)
Nat Rev Drug Discov. 2020 Nov;19(11):776-800. (PMID: 32929243)
ACS Nano. 2019 Nov 26;13(11):12511-12524. (PMID: 31664821)
Mol Ther. 2016 Feb;24(2):364-374. (PMID: 26334519)
EMBO J. 1992 Nov;11(11):3887-95. (PMID: 1396582)
MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9. (PMID: 20508593)
Nat Prod Rep. 2017 Feb 1;34(2):194-219. (PMID: 27874907)
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. (PMID: 30523282)
Clin Cancer Res. 2007 Jul 15;13(14):4170-7. (PMID: 17634545)
ACS Nano. 2017 May 23;11(5):4916-4925. (PMID: 28414916)
Biomed Pharmacother. 2017 Dec;96:378-383. (PMID: 29031195)
Biochem Pharmacol. 1992 May 28;43(10):2237-45. (PMID: 1599509)
Cytokine. 2008 May;42(2):145-151. (PMID: 18304834)
Cancer. 2000 Jun 15;88(12):2686-92. (PMID: 10870050)
J Immunol. 1989 Sep 1;143(5):1482-9. (PMID: 2474600)
Cell Death Dis. 2018 Oct 10;9(10):1039. (PMID: 30305604)
Mol Immunol. 2016 Mar;71:42-53. (PMID: 26851529)
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7. (PMID: 12826605)
Nat Rev Microbiol. 2021 Apr;19(4):222-223. (PMID: 33597747)
ACS Appl Mater Interfaces. 2019 Aug 7;11(31):27536-27547. (PMID: 31294958)
Mol Cancer. 2015 Sep 24;14:174. (PMID: 26403780)
Mol Cell. 2019 Nov 7;76(3):359-370. (PMID: 31668929)
Oncotarget. 2014 Dec 30;5(24):12472-508. (PMID: 25537519)
Annu Rev Immunol. 2013;31:51-72. (PMID: 23157435)
Infect Agent Cancer. 2019 Oct 18;14:27. (PMID: 31636696)
Int J Biol Macromol. 2020 May 1;150:261-280. (PMID: 32044366)
J Pathol. 2002 Mar;196(3):254-65. (PMID: 11857487)
Sci Adv. 2020 Feb 05;6(6):eaay7785. (PMID: 32076650)
Immunity. 2013 Jul 25;39(1):38-48. (PMID: 23890062)
Carcinogenesis. 2010 Apr;31(4):719-28. (PMID: 20110283)
Cancer Immunol Immunother. 2005 Jul;54(7):694-702. (PMID: 15726361)
Immunol Lett. 2003 Apr 3;86(2):123-9. (PMID: 12644313)
PLoS One. 2014 Nov 12;9(11):e110040. (PMID: 25391149)
Eur J Immunol. 1997 Dec;27(12):3135-42. (PMID: 9464798)
Nat Prod Rep. 2017 Jan 4;34(1):25-61. (PMID: 27759131)
Nat Biotechnol. 2016 Oct 11;34(10):1019-1024. (PMID: 27727216)
BMJ. 2015 Apr 22;350:h988. (PMID: 25904595)
Cancer Immunol Immunother. 2019 Jul;68(7):1059-1071. (PMID: 30972427)
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5120-5. (PMID: 15793000)
J Biol Chem. 2009 Feb 6;284(6):3700-8. (PMID: 19075017)
J Am Chem Soc. 2010 Feb 17;132(6):1939-45. (PMID: 20088518)
Nat Rev Immunol. 2020 Aug;20(8):483-497. (PMID: 32024984)
Biomed Pharmacother. 2019 Sep;117:109167. (PMID: 31387180)
J Immunol. 2005 May 1;174(9):5224-32. (PMID: 15843518)
Cancer Res. 2006 Jan 15;66(2):605-12. (PMID: 16423985)
Int Immunopharmacol. 2019 Oct;75:105824. (PMID: 31437792)
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371. (PMID: 30705439)
Biotechnol Adv. 2020 Jan - Feb;38:107342. (PMID: 30708024)
Lancet Oncol. 2015 Feb;16(2):e56. (PMID: 25532625)
Cell Mol Biol (Noisy-le-grand). 2018 Jun 25;64(8):27-34. (PMID: 29981688)
Prog Drug Res. 2014;68:181-208. (PMID: 24941670)
Cancer Biother Radiopharm. 2018 Feb;33(1):25-31. (PMID: 29466034)
Chin J Integr Med. 2008 Mar;14(1):33-6. (PMID: 18219455)
Small. 2019 Jun;15(24):e1900631. (PMID: 31033217)
Int J Pharm. 2019 Jan 10;554:72-80. (PMID: 30399435)
Clin Exp Immunol. 2002 Jul;129(1):4-10. (PMID: 12100016)
J Headache Pain. 2019 Mar 25;20(1):30. (PMID: 30909864)
Science. 2018 Jan 5;359(6371):97-103. (PMID: 29097493)
Clin Cancer Res. 2017 Oct 15;23(20):6054-6061. (PMID: 28724663)
Cancer Res. 2006 Jun 1;66(11):5527-36. (PMID: 16740684)
Cell. 2001 Aug 10;106(3):259-62. (PMID: 11509173)
Front Immunol. 2020 Feb 20;11:62. (PMID: 32153559)
Immunol Rev. 2007 Jun;217:65-78. (PMID: 17498052)
Nat Rev Drug Discov. 2019 Mar;18(3):197-218. (PMID: 30610226)
Phytomedicine. 2017 Nov 7;:. (PMID: 29239784)
Nat Med. 2002 Aug;8(8):793-800. (PMID: 12091876)
Cancer Immunol Immunother. 2005 Apr;54(4):307-14. (PMID: 15599732)
Eur J Immunol. 2003 Aug;33(8):2168-77. (PMID: 12884291)
Lancet Oncol. 2020 Sep;21(9):e419-e430. (PMID: 32888471)
Cancer Immunol Immunother. 2012 Nov;61(11):1989-2002. (PMID: 22527248)
Vaccine. 2009 Mar 13;27(12):1787-96. (PMID: 19208455)
Acc Chem Res. 2016 Sep 20;49(9):1741-56. (PMID: 27568877)
Annu Rev Immunol. 2007;25:267-96. (PMID: 17134371)
Cancer Immunol Immunother. 2010 Aug;59(8):1259-72. (PMID: 20390417)
Int Immunopharmacol. 2020 Apr;81:106206. (PMID: 32018066)
Sci Transl Med. 2018 Feb 21;10(429):. (PMID: 29467301)
Biomark Insights. 2011 Feb 28;6:27-38. (PMID: 21499439)
Nat Rev Immunol. 2005 May;5(5):375-86. (PMID: 15864272)
Adv Immunol. 2000;74:181-273. (PMID: 10605607)
Nature. 2011 Dec 21;480(7378):480-9. (PMID: 22193102)
PLoS One. 2015 Feb 27;10(2):e0116191. (PMID: 25723174)
Vaccine. 2014 Jan 9;32(3):401-8. (PMID: 24252697)
Cell Cycle. 2016 Dec 16;15(24):3413-3418. (PMID: 27753543)
Clin Cancer Res. 2019 Feb 15;25(4):1142-1146. (PMID: 30309857)
Int Immunopharmacol. 2018 Sep;62:29-39. (PMID: 29990692)
J Tradit Complement Med. 2014 Jan;4(1):42-8. (PMID: 24872932)
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6094-100. (PMID: 15447995)
Clin Cancer Res. 2004 Mar 1;10(5):1670-7. (PMID: 15014018)
Semin Cancer Biol. 2019 Dec;59:266-282. (PMID: 31233829)
Am J Cancer Res. 2020 Jan 01;10(1):1-11. (PMID: 32064150)
Cancer Res. 2004 Feb 1;64(3):1071-8. (PMID: 14871840)
Evid Based Complement Alternat Med. 2011;2011:274858. (PMID: 19001481)
Vaccine. 2000 Jul 15;18(27):3141-51. (PMID: 10856794)
Front Pharmacol. 2020 Jan 29;10:1658. (PMID: 32063859)
Vaccine. 2018 Aug 23;36(35):5226-5234. (PMID: 30057282)
Cancer Res. 2015 Dec 1;75(23):5034-45. (PMID: 26573793)
Cancer Immunol Immunother. 2007 Dec;56(12):1921-30. (PMID: 17619878)
Int J Cancer. 2012 Jun 1;130(11):2618-28. (PMID: 21792901)
Chem Soc Rev. 2018 Jan 22;47(2):514-532. (PMID: 29154385)
Vaccine. 2012 Jan 5;30(2):388-97. (PMID: 22079266)
Cancer Lett. 2018 Apr 28;420:210-227. (PMID: 29410006)
Nat Rev Cancer. 2004 Jan;4(1):71-8. (PMID: 14708027)
MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):630-2. (PMID: 20508594)
J Immunol. 2002 Jun 1;168(11):5491-8. (PMID: 12023343)
Cancer Lett. 2018 May 28;422:9-18. (PMID: 29471004)
Semin Cancer Biol. 2017 Oct;46:84-106. (PMID: 28676460)
Antioxidants (Basel). 2019 Apr 16;8(4):. (PMID: 30995775)
Nat Rev Immunol. 2005 Dec;5(12):953-64. (PMID: 16322748)
World J Surg Oncol. 2018 Jun 14;16(1):108. (PMID: 29898731)
Science. 2015 Apr 3;348(6230):62-8. (PMID: 25838374)
Anticancer Res. 2019 Oct;39(10):5231-5259. (PMID: 31570421)
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81. (PMID: 10500201)
Clin Cancer Res. 2016 Jul 1;22(13):3127-31. (PMID: 27146699)
Clin Cancer Res. 2011 Jun 1;17(11):3520-6. (PMID: 21471425)
PLoS One. 2015 Mar 31;10(3):e0122374. (PMID: 25825910)
Immune Netw. 2016 Feb;16(1):75-84. (PMID: 26937234)
Drug Des Devel Ther. 2020 Feb 28;14:907-919. (PMID: 32184560)
Vaccine. 1994 Nov;12(14):1275-80. (PMID: 7856291)
Biochem Pharmacol. 2019 Apr;162:55-70. (PMID: 30615863)
Immunity. 1998 Dec;9(6):839-47. (PMID: 9881974)
Clin Cancer Res. 2019 Apr 15;25(8):2610-2620. (PMID: 30647079)
J Immunol. 2020 Feb 1;204(3):622-631. (PMID: 31871020)
Arch Biochem Biophys. 2004 Mar 1;423(1):88-96. (PMID: 14871471)
Mol Med Rep. 2013 Nov;8(5):1580-6. (PMID: 24065177)
Pharmacol Res. 2020 Feb;152:104623. (PMID: 31899315)
Science. 1996 Mar 22;271(5256):1734-6. (PMID: 8596936)
Pharmacol Res. 2020 May;155:104727. (PMID: 32113874)
فهرسة مساهمة: Keywords: AKT, alpha-serine/threonine-specific protein kinase; Adoptive immune-cells transfer immunotherapy; B2M, beta-2-microglobulin; BMDCs, bone marrow dendritic cells; BPS, basil polysaccharide; BTLA, B- and T-lymphocyte attenuator; CAFs, cancer-associated fibroblasts; CCL22, C–C motif chemokine 22; CIKs, cytokine-induced killer cells; COX-2, cyclooxygenase-2; CRC, colorectal cancer; CTL, cytotoxic T cell; CTLA-4, cytotoxic T lymphocyte antigen-4; Cancer immunotherapy; Cancer vaccines; DAMPs, damage-associated molecular patterns; DCs, dendritic cells; FDA, US Food and Drug Administration; HCC, hepatocellular carcinoma; HER-2, human epidermal growth factor receptor-2; HIF-1α, hypoxia-inducible factor-1α; HMGB1, high-mobility group box 1; HSPs, heat shock proteins; ICD, Immunogenic cell death; ICTs, immunological checkpoints; IFN-γ, interferon γ; IL-10, interleukin-10; Immuno-check points; Immunosuppressive microenvironment; LLC, Lewis lung cancer; MDSCs, myeloid-derived suppressor cells; MHC, major histocompatibility complex class; MITF, melanogenesis associated transcription factor; MMP-9, matrix metalloprotein-9; Mcl-1, myeloid leukemia cell differentiation protein 1; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NKTs, natural killer T cells; NSCLC, non-small cell lung cancer; Natural products; OVA, ovalbumin; PD-1, programmed death-1; PD-L1, programmed death receptor ligand 1; PGE-2, prostaglandin E2; PI3K, phosphoinositide 3-kinase; ROS, reactive oxygen species; STAT3, signal transducer and activator of transcription 3; TAMs, tumor-associated macrophages; TAP, transporters related with antigen processing; TGF-β, transforming growth factor-β; TILs, tumor infiltration lymphocytes; TLR, Toll-like receptor; TNF-α, tumor necrosis factor α; TSA, tumor specific antigens; Teffs, effective T cells; Th1, T helper type 1; Tregs, regulatory T cells; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; mTOR, mechanistic target of rapamycin
تواريخ الأحداث: Date Created: 20220509 Latest Revision: 20220716
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9069318
DOI: 10.1016/j.apsb.2021.08.020
PMID: 35530162
قاعدة البيانات: MEDLINE
الوصف
تدمد:2211-3835
DOI:10.1016/j.apsb.2021.08.020